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Abstract
Background—Observational and experimental studies suggest that vitamin D may influence
breast cancer etiology. Most known effects of vitamin D are mediated via the vitamin D receptor
(VDR). Few polymorphisms in the VDR gene have been well studied in relation to breast cancer
risk and results have been inconsistent.
Methods—We investigated VDR polymorphisms and haplotypes in relation to breast cancer risk
by genotyping 26 single nucleotide polymorphisms (SNPs) that i) had known/suspected impact on
VDR function, ii) were tagging SNPs for the three VDR haplotype blocks among whites, or iii)
were previously associated with breast cancer risk. We estimated odds ratios (OR) and 95%
confidence intervals (CI) in relation to breast cancer risk among 270 incident cases and 554
matched controls within the Agricultural Health Study cohort.
Results—In individual SNP analyses, homozygous carriers of the minor allele for rs2544038 had
significantly increased breast cancer risk (OR=1.5; 95% CI: 1.0, 2.5) and homozygous carriers of
the minor allele for rs11168287 had significantly decreased risk (OR=0.6; 95% CI: 0.4, 1.0).
Carriers of the minor allele for rs2239181 exhibited marginally significant association with risk
(OR=1.4; 95% CI: 0.9, 2.0). Haplotype analyses revealed three haplotype groups (blocks “A”,
“B”, and “C”). Haplotype GTCATTTCCTA in block B was significantly associated with reduced
risk (OR=0.5; 95% CI: 0.3, 0.9).
Conclusions—These results suggest that variation in VDR may be associated with breast cancer
risk.
Impact—Our findings may help guide future research needed to define the role of vitamin D in
breast cancer prevention.
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Evidence from observational and experimental studies suggests that vitamin D may
influence breast cancer development. A growing number of epidemiologic studies have
reported decreased risk of breast cancer associated with exposure to sunlight/UV radiation
(1–14), which results in dermal synthesis of vitamin D and is the primary source of this
vitamin for most people (15). A recent meta-analysis suggests a small inverse association
between dietary vitamin D and breast cancer risk (16), although the literature on this
association is inconsistent and may reflect the relatively small contribution of diet to
circulating vitamin D levels in the general population (15). Serum vitamin D levels have
been consistently associated with reduced risk of breast cancer in case-control studies (17,
18), but not in most nested case-control studies (17, 19). Additional evidence for the
anticancer effects of vitamin D comes from in vitro studies showing that the biologically
active form of vitamin D, 1,25-dihydroxyvitamin D, decreases proliferation and promotes
differentiation and apoptosis in breast cancer cell lines (20–22).
Most of the known physiological effects of vitamin D are mediated via binding of 1,25-
dihydroxyvitamin D to the vitamin D receptor (VDR) (23). The VDR, which belongs to the
nuclear hormone receptor superfamily, is a transcription regulator expressed in almost all
tissue, including normal breast tissue and most breast tumors (24). It regulates transcription
of a range of genes, including ones involved in cellular growth, differentiation, apoptosis,
angiogenesis, and metastasis (23, 25, 26). Importantly, experimental studies on mammary
tumor cell lines from VDR-knockout mice demonstrate that VDR is necessary for induction
of cell cycle arrest and apoptosis in breast cancer cells by 1,25-dihydroxyvitamin D (27).
Moreover, VDR-deficient mice show an enhanced susceptibility to tumorigenesis in the
breast and other tissue (28). Taken together, these prior findings suggest the need to study
the role of VDR polymorphisms in relation to breast cancer risk in humans.
VDR is encoded by a large gene located on chromosome 12cen-q12 (29) that contains 14
exons spanning approximately 75 kb (30, 31). Although the VDR gene has been well
characterized and a large number of polymorphisms identified (32, 33), only a few of these
have been previously examined in relation to breast cancer risk. Most have been tested with
restriction enzymes and are of unknown or uncertain functional effect, although one, FokI,
has been shown to alter the length and activity of the protein product (34). In previous
linkage disequilibrium (LD) analyses of single nucleotide polymorphisms (SNPs) in VDR, it
has been shown that the SNPs constitute three LD blocks (32). FokI is not in LD with any
other SNPs (32). The other commonly studied SNPs, BsmI, ApaI, and TaqI, are all in the
same LD block and predict only 38% of the SNPs in that block with R2 > 0.8, capturing no
information about SNPs in the other two blocks in VDR among whites (32). Therefore,
studies that genotyped only these SNPs captured no information on a large fraction of
common SNPs in VDR. This may partially explain why epidemiologic studies to date of
VDR polymorphisms and breast cancer risk have reported largely inconsistent results.
Specifically, studies of FokI in relation to breast cancer risk have reported some evidence of
increased risk among ff carriers (35–39), decreased risk among ff carriers (40), or no
association (3, 41–45). Similarly mixed results have been observed in relation to breast
cancer risk for other polymorphisms, including BsmI, with associations in some studies (39,
43, 45–47) but not others (35, 37–40, 44); for ApaI, with some findings positive (42, 48) and
others null (40, 44); and for TaqI, with associations in some studies (36, 41, 42), but not
others (3, 37, 40, 44, 49, 50). While some of these inconsistencies may result from
differences in study design or study population, it is possible, given the size of the VDR
gene, that any causal genetic variant(s) remains to be identified. The aim of the present study
was to conduct an extensive analysis of haplotypes and individual polymorphisms in VDR
in relation to risk of breast cancer in a prospective cohort.
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The Agricultural Health Study cohort was established between 1993 and 1997 and includes
private pesticide applicators (primarily farmers) and their wives from Iowa and North
Carolina (51). All 43,475 male private pesticide applicators who indicated at enrollment that
they were married were requested to ask their wives to complete two take-home
questionnaires. One questionnaire elicited information on the wives’ farm exposures and
general health (“spouse enrollment questionnaire”) while the other focused on their
reproductive health history (“female and family health questionnaire”). A total of 32,127
wives (74% of eligible wives) enrolled in the cohort. Of these, 19,578 (61% of those
enrolled) completed both questionnaires while 12,549 (39% of those enrolled) completed
only the spouse enrollment questionnaire. In addition, 23,676 wives (74% of those enrolled)
completed a detailed follow-up telephone interview approximately 5 years after enrollment,
at which time they were asked to provide a mouthwash rinse sample for extraction of DNA
from buccal cells; approximately 60% of these participants returned a sample. Over 98% of
the wives in this cohort are white.
Participant follow-up and case ascertainment
Breast cancer cases were identified through population-based cancer registries in Iowa and
North Carolina. Estrogen receptor and progesterone receptor status of the tumor was
available from the registries for 74.4–75.4% of cases. Cases had no cancer diagnoses prior to
enrollment and were diagnosed with malignant breast cancer (International Classification of
Diseases for Oncology second edition, C50.0–C50.9) between enrollment and December 31,
2004 (i.e., incident cases, n=578). Only 263 cohort members (0.8%) moved out of state and
were consequently lost to follow-up during the study period.
All eligible breast cancer cases and potential controls who had previously provided a
mouthwash rinse sample for extraction of DNA as part of the parent study were eligible for
the present study. Of the 578 incident cases in the cohort, 293 (50.7%) had provided
mouthwash samples and were, therefore, selected as cases for this study. Importantly,
previous analyses found little difference in demographic, lifestyle, occupational, or medical
factors between members of the cohort who returned a mouthwash sample and those who
did not, suggesting that selection bias related to provision of this sample is unlikely (52).
Two controls were randomly matched with replacement to each case by race (white, other),
state (Iowa, North Carolina), age at enrollment (5 year age groups), and enrollment period
(1993–1995, 1996–1997); controls had to be alive, have no cancer diagnoses, and be living
in state at the date of diagnosis of their corresponding case. A total of 879 cases and controls
were selected. Due to controls being selected with replacement, which provides an unbiased
sample from the cohort (53), 19 subjects were each selected as controls for two cases and
four subjects were each selected as both a control and, at a later time point, a case. Informed
consent was obtained and the study protocol was reviewed by all relevant Institutional
Review Boards.
DNA extraction and genotyping
DNA was extracted from buccal cells using the QIAamp 96 DNA Blood Kit (QIAGEN Inc.,
Valencia, CA). DNA concentration was measured by spectrophotometry at 260 nm and
DNA quality was determined by the A260/A280 ratio. Sufficient DNA for genotyping,
without consuming all available DNA, was obtained from 802 (93.7%) samples. These
represented 270 cases and 554 controls, including 18 subjects selected as controls for two
cases and four subjects who were each selected as both a control and, at a later date, a case.
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We selected 27 SNPs, based partially on the results of Nejentsev et al. (32), who performed
sequencing and extensive genotyping of the VDR gene among multiple populations of
Europeans and Africans and identified the minimal set of haplotype tag SNPs (htSNPs).
These SNPs were selected as htSNPs to capture the genetic variation within the three
haplotype blocks among whites (32), and also included SNPs with known or suspected
impact on VDR function or that had been associated with breast cancer risk in previous
studies. They included rs2544038, rs739837, rs731236 (TaqI), rs2239182, rs2107301,
rs2239181, rs2238139, rs2189480, rs3782905, rs7974708, rs11168275, rs2408876,
rs1989969, rs2238135, rs10875694, rs3922882, rs11168287, rs7299460, rs11168314,
rs4303288, rs4073729, rs3923693, rs4760674, rs6823, rs2071358, rs7975232 (ApaI), and
rs2228570 (FokI, formerly reported as rs10735810). One SNP, rs4303288, could not be
successfully genotyped due to poor clustering and non-specific signals and, therefore, is not
included in the following analyses. One of the SNPs (rs2228570), at a FokI restriction site,
was included because it is known to alter the VDR protein (34) but has no detectable linkage
with any other SNP and is, therefore, not in a haplotype block. The SNPs rs731236 (TaqI)
and rs7975232 (ApaI) had previously been studied in relation to breast cancer and other
diseases (3, 36, 37, 40–42, 44, 48–50). All selected SNPs have a minor allele frequency of at
least 10% in whites. To facilitate comparison with previous literature, the following
provides the correspondence between nucleotides and restriction fragment length
polymorphism nomenclature for major and minor alleles genotyped in this study: FokI
(rs2228570): C=F, T=f; ApaI (rs7975232): A=A, C=a; TaqI (rs731236): T=T, C=t.
Twenty-four SNPs were genotyped by mass spectrometry and two SNPs were genotyped
with pyrosequencing. Primer sequences are described in detail in the Supplementary
Material (Tables S1 and S2). The genotyping by mass spectrometry was done on the
Sequenom MassARRAY iPLEX genotyping Platform (Sequenom Inc., San Diego, CA) in
seven multiplex assays. Experiments were designed with the RealSNP Assay Database and
the MassArray software v.3.1. Twenty nanograms of genomic DNA were amplified using
specific primers, reagents, and cycling conditions detailed in the Supplementary Material
(Table S1). The products were desalted and then spotted onto a 384 SpectroCHIP bioarray
(Sequenom). Cluster plots were evaluated with the TyperAnalyzer application
(MassARRAY v.3.4). Assays were considered optimal according to degree of clustering,
absence of signal in the blanks, and when sequencing of representative samples within the
clusters confirmed the genotypes. Two SNPs that failed to cluster or showed suboptimal
performance on mass array (rs3923693 and rs7975232) were tested with pyrosequencing
(54) using the AB PSQ™ MA instrument (Qiagen Inc., Valencia, CA). Specific primers,
reaction, and cycling conditions are available in Table S2. All reactions contained known
internal controls, and standard precautions to avoid contamination were followed. Quality
control included review of clusters and specificity, 5% randomly selected repeats, as well as
interpretation of results and verification of data and data entry by an independent laboratory
member. The genotype frequencies among controls did not differ from the expected Hardy-
Weinberg equilibrium proportions.
Data analysis
We used conditional logistic regression to estimate odds ratios (OR) and 95 percent
confidence intervals (CI) to account for the matched design of the study. All analyses were
adjusted for known breast cancer risk factors, including age at menopause (premenopausal,
and postmenopausal in the following age groups: < 45, 45–49, 50–54, ≥ 55 years), first
degree family history of breast cancer (yes and no), parity, and age at first birth. Parity and
age at first birth were combined (1 birth by age 30 years; ≥2 births, first of which was by age
30 years; nulliparous or all births after age 30 years), with nulliparous women and those
with first births after age 30 years combined because of the small number of nulliparous
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women in this study (4 cases and 7 controls). Body mass index, age at menarche, smoking
status, and education were examined as potential confounders but were not included in the
final models because they did not materially change the risk estimates. We used last-
reported values prior to diagnosis for cases or reference date for controls for all time-varying
covariates.
Because some members of matched case-control sets (one case and two controls per set) had
missing information on genotype or haplotype, we used the missing-indicator method (55) to
retain all subjects and maintain case-control matching. This method produces an odds ratio
estimate that is a compromise between the estimate by a matched analysis of the complete
sets and by an unmatched analysis of the incomplete sets. Missing covariate data were
imputed using the IVEware program (56). This program simultaneously imputes values for
specified variables by fitting a sequence of regression models and drawing values from the
corresponding predictive distributions. Missing values were imputed for race (3.2%), family
history of breast cancer (5.0%), parity (17.6%), age at menopause (21.8%), and use of
hormone replacement therapy (9.8%). Risk estimates that included imputed data were not
materially different from those that included only observed data, so we present risk
estimates adjusted using these imputed and observed data.
Our primary interest in this paper is in the evaluation of haplotypes. We first provide results
for the individual SNP analyses, followed by the haplotype analyses. For each SNP,
conditional logistic regression analysis was used to estimate the odds ratios and 95%
confidence intervals of the heterozygous and homozygous (for the minor allele) genotype
groups. For the haplotype analyses, we first determined the haplotype structure, particularly
the haplotype blocks, of our study population using haploview v4.1 (57) among control
subjects. Because the genotype data were unphased, we estimated the haplotype frequencies
and the expected haplotypes using the haplo.stats software package (58) in R v2.3 (59) and
used these as independent variables in regression models, as described by Kraft et al. (60).
Only the most common 50% of haplotypes for each haplotype block, ranging in prevalence
from 4.7% to 20.1%, are shown in the tables, although all haplotypes were included in the
analyses.
We also conducted analyses stratified by menopausal status at diagnosis, family history of
breast cancer, state of residence, and estrogen receptor (ER; NER+=170, NER−=51) and
progesterone receptor (PR; NPR+=150, NPR−=68) status of the tumor. These stratified case-
control analyses were conducted using unconditional logistic regression.
All statistical analyses were performed using SAS v9.1 (61), except where otherwise noted.
All statistical significance was assessed at the 5% level. We did not adjust the p-values for
multiple comparisons due to the exploratory nature of our extensive evaluations of the
individual SNPs and haplotypes. All data used in these analyses were based on Agricultural
Health Study data releases P1REL0506.01 and P2REL0506.04.
Results
Selected characteristics of the subjects in this case-control study are provided in Table 1.
The mean age was 58.3±10.0 years for cases at diagnosis and 62.8±8.9 years for their
matched controls. The large majority of cases and controls were white (approximately 98%
of each). Only 1.4% of cases and 1.2% of controls were nulliparous. About 67.8% of cases
at diagnosis and 68.1% of controls were post-menopausal. Risk of breast cancer was
significantly increased among women reporting a family history of breast cancer (OR=1.8;
95% CI: 1.2, 2.6). Risk was also increased among women who either were nulliparous or
had a first birth after age 30 years compared to women with two or more births, the first of
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which was by age 30 years (OR=2.1; 95% CI: 1.2, 3.8). Among premenopausal women,
breast cancer risk was significantly reduced among those with BMI of 30 kg/m2 or above
(OR=0.3; 95% CI: 0.1, 0.8) compared to those with BMI less than 25 kg/m2; however, this
was based on only 9 cases in the high BMI category. Breast cancer risk was elevated among
former and current smokers relative to never smokers, although the increases were not
statistically significant (OR=1.8 [95% CI: 0.9, 3.6] among former smokers and OR=2.0
[95% CI: 0.9, 4.2] among current smokers).
The haplotype structure of our study population (Fig 1) was comparable to that observed
among whites by Nejentsev et al. (32). Therefore, blocks were defined using the naming
convention of Nejentsev et al. (32), with htSNPs in the following positional order – Block
A: rs2544038; Block B: rs739837, rs731236, rs7975232, rs2239182, rs2107301, rs2239181,
rs2238139, rs2189480, rs3782905, rs7974708, rs11168275; Block C: rs2408876, rs1989969,
rs2238135, rs10875694, rs3922882, rs11168287, rs7299460, rs11168314, rs4073729,
rs3923693, rs4760674, rs6823, rs2071358.
The locus rs2228570 (FokI), which was not in LD with any other SNP, was not significantly
associated with altered risk of breast cancer (OR=1.3 (0.9, 1.7) for C/T and 1.2 (0.7, 1.9) for
T/T, relative to C/C; p for trend=0.31) (Table 2). The SNP rs2544038 (in haplotype block A)
was associated with increased risk of breast cancer (OR=1.3 (0.9, 1.8) for C/T and 1.5 (1.0,
2.5) for C/C, relative to T/T; p for trend=0.05), although the risk for heterozygous carriers
was only marginally significant. In addition, rs11168287 (in haplotype block C) was
associated with decreased risk (OR=0.7 (0.5, 1.1) for A/G and 0.6 (0.4, 1.0) for G/G, relative
to A/A; p for trend=0.05), but the risk among heterozygous carriers was only marginally
significant. Finally, rs2239181 (in haplotype block B) exhibited a marginally significant
association with breast cancer risk (OR=1.4 (0.9, 2.0) for G/T or G/G relative to T/T;
p=0.09).
The haplotype GTCATTTCCTA in LD block B (denoted haplotype “B4”) was significantly
associated with decreased risk of breast cancer, with OR=0.5 (0.3, 0.9) (Table 3). In
statistical models that included all of the htSNPs in block B simultaneously, rs2239181 had
a significantly increased risk (1.6 [1.0, 2.7] for G/G or G/T vs. T/T); no other htSNP in
block B approached statistical significance.
Results did not differ substantively between subgroups defined by family history of breast
cancer or in subanalyses restricted to whites (data not shown). Results were similar between
Iowa and North Carolina (data not shown). In analyses stratified by menopausal status, the
risk associated with rs2408876 appeared to differ for premenopausal vs. postmenopausal
women (premenopausal: OR=0.5 (0.3, 0.9) for T/C and OR=0.7 (0.3, 1.6) for C/C, relative
to T/T; postmenopausal: OR=1.6 (1.1, 2.4) for T/C and OR=1.8 (1.0, 3.2) for C/C, relative
to T/T). When analyses were stratified by ER status and PR status, the risk associated with
rs2544038 was apparently stronger in ER− and PR− cases, although confidence intervals
were wide and overlapping (ER−: OR=2.3 (1.0, 4.9) for C/T and OR=2.9 (1.2, 7.2) for C/C,
relative to T/T; ER+: OR=1.2 (0.8, 1.8) for C/T and OR=1.4 (0.8, 2.3) for C/C, relative to T/
T; PR−: OR=2.3 (1.2, 4.5) for C/T and OR=2.7 (1.2, 6.1) for C/C, relative to T/T; PR+:
OR=1.1 (0.7, 1.7) for C/T and OR=1.3 (0.8, 2.3) for C/C, relative to T/T).
Discussion
Results from this case-control study nested within a large, prospective cohort provide
limited evidence that variants of the VDR gene may be related to risk of breast cancer.
Haplotype GTCATTTCCTA in LD block B was observed to be associated with a reduced
risk. Among individual SNPs, breast cancer risk was observed to be significantly associated
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with rs2544038 (block A) and rs11168287 (block C), and to have a marginally significant
association with rs2239181 (block B).
To our knowledge, this study is the first to examine comprehensive haplotypes in the VDR
gene in relation to breast cancer risk. Most previous studies have examined individual
polymorphisms, focusing primarily on the restriction fragment length polymorphisms BsmI
(rs1544410), FokI (rs2228570), ApaI (rs7975232), and TaqI (rs731236). Results of these
studies have been inconsistent. The weight of evidence tends to be strongest for an
association with FokI. Among the studies that examined FokI in relation to breast cancer
risk (3, 35–45), several provided some evidence of increased risk among carriers of the ff
genotype (35–39), with odds ratios ranging between 1.16 and 2.34. Apart from one case-
control study that reported a significantly decreased relative risk of 0.71 among ff carriers
(40), the remaining studies found no association. The reasons for this discrepancy remain
unclear, although it may be due in part to differences across studies in sample size, race/
ethnicity of study populations, or control selection. FokI is not in LD with any other SNPs
(32). A meta-analysis that included most of the above studies (i.e., all studies published
through October 2008) (62) suggested a small, but significantly, increased risk of breast
cancer among Fok1 ff carriers compared to FF carriers (summary OR=1.15; 95% CI = 1.03,
1.28). Our estimated OR of 1.2 was consistent in direction and magnitude with this summary
OR, but was not statistically significant. This SNP did not depart from Hardy-Weinberg
equilibrium among controls in our study and the minor allele frequency was similar to that
of other white populations. An effect of this SNP is plausible, given that the f allele results
in production of a VDR protein that is less effective as a transcriptional activator (34), the
consequences of which would be expected to mimic that of lower vitamin D status.
Two studies that examined VDR haplotypes (41, 44) used only a small number of
polymorphisms that likely did not capture a large fraction of the variation in this gene (32).
One of these studies inferred haplotypes from only BsmI, ApaI, TaqI, and a poly(A) repeat
and found no association between any haplotype and breast cancer risk (44). The other study
inferred haplotypes from the FokI, TaqI, VDR-5132, and Cdx2 polymorphisms, and found
increased risk of breast cancer associated with the haplotype containing FokI F, TaqI t,
VDR-5132 C, and Cdx2 A (41). These results and those of the present study cannot be
directly compared because of differences in haplotype definitions (32). Moreover, while
some in vitro studies of VDR haplotypes have reported higher mRNA expression for the
BsmI-ApaI-TaqI haplotype BAt (rs1544410-A/rs7975232-A/rs731236-C) than for the
haplotype baT (rs1544410-G/ rs7975232-C/rs731236-T), other studies have observed the
opposite pattern not only for mRNA expression, but also for mRNA stability and
transactivation, which could be due in part to differences in the cell lines used (63).
In the present study, we identified one haplotype, GTCATTTCCTA in LD block B, that was
significantly associated with a 50% reduced risk of breast cancer. While we are unaware of
comparable haplotype data from other studies, a number of studies have investigated several
individual SNPs within this block. Our results for SNPs within block B are consistent with a
meta-analysis of commonly examined VDR SNPs (62), which found no significant
associations between Bsm1, Apa1, or Taq1, which are in this block, and risk of breast
cancer. Reports published since this meta-analysis are also largely consistent with these
findings (36, 37, 39, 40, 45). Although we did not test BsmI, we did test rs731236, which is
in strong LD (r2=0.97) with BsmI among whites (64) and which showed no association with
breast cancer risk. In addition, a recent case-control study (40) that included several of the
less commonly-studied SNPs assessed in the present study also supports our findings of no
effect associated with rs739837, rs1989969, rs2107301, and rs2238135, which are found in
blocks B and C. Our haplotype results, if confirmed, would suggest that another
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polymorphism or polymorphisms in strong LD with rs2239181 may be responsible for the
reduced risk associated with this haplotype.
We found only limited evidence of differences in risk by menopausal status or by ER/PR
status of the tumor. Previous studies that investigated interactions between menopausal
status and VDR variants on breast cancer risk have found little evidence of effect
modification (35, 39, 40, 45, 46). At the same time, evidence is limited and inconsistent for
a modification of effect of VDR variants by ER or PR status. FokI ff was found to have a
marginally and nonsignificantly stronger association with ER−/PR− tumors than ER+/PR+
tumors in one study (39) and the TaqI t allele was associated with a significantly increased
breast cancer risk only in ER+ tumors in another study (41); however, no modification of
effect by ER or PR status was found in other studies in which it was investigated (35, 36,
46). We observed no differences in risk for FokI or TaqI by ER or PR status and we are
unaware of other studies that examined modification of the association of rs2544038 and
breast cancer risk by ER or PR status.
The heterogeneity of observed associations across studies may be due in part to differences
in vitamin D status of study populations. Persons living on farms may receive more UV
exposure and have different diets than the general population, which could influence
circulating vitamin D levels during certain periods. In contrast to the static genetic variation
investigated herein, these exposures are complex and time-varying. The interaction between
markers of vitamin D status and VDR variants on breast cancer risk in this cohort will be
investigated in detail in the future.
The observed association between smoking and breast cancer risk is consistent with the
conclusions of a recent expert panel on tobacco smoke and breast cancer risk, which
concluded that the relationship between active smoking and breast cancer is consistent with
causality (65). Results from two large prospective cohort studies published subsequent to
this report (66, 67) support this conclusion. Although this association remains controversial,
further discussion is beyond the scope of this paper.
Limitations of this study include the availability of DNA for only about 51% of the cases in
the cohort. However, previous analyses suggest that this was unlikely to introduce selection
bias (52). The study sample size was relatively small, especially for stratified analyses,
though we had sufficient power to detect modest associations in the full sample. Also, there
were too few non-whites in this cohort to separately examine associations among these
subjects. Exclusion of non-whites from analyses had minimal impact on risk estimates.
Lastly, given the number of comparisons that were performed, we cannot exclude the
possibility that the observed associations occurred by chance.
This study had a number of strengths. These include detailed data at baseline and at 5 years
follow-up on potential confounding factors. The availability of data collected prior to
disease diagnosis mitigated concerns about survival or reporting bias. Moreover, reliability
of these data was shown to be good to excellent for a range of factors among cohort
members who completed the same questionnaire at least one year apart (68). We were able
to capture and incorporate into our analyses much of the variation in the VDR gene by using
an extensive set of haplotype tag SNPs. Finally, we were able to compare results between
both states in this cohort, which provided some evidence of internal consistency.
These results provide limited evidence that variation in the VDR gene may be associated
with risk of breast cancer. The modest magnitude and borderline significance of most of
these associations necessitate caution in their interpretation. Further years of follow-up of
this cohort, with inclusion of additional incident cases and follow-up data in future analyses,
should help to clarify the relationship between VDR variants and the risk of breast cancer.
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